 is rated "Unattractive" in both our US Large-Cap and US Consumer Discretionary Global Top Stock Ideas. Merck (MRK GR) cut its full year adjusted ebitda forecast while raising its net sales guidance. Merck expects full year adjusted ebitda 0.0-0.0 billion euros, down from 0.00-0 billion euros. Merck now expects organic net sales to grow 0-0%, up from 0-0%. Merck said adverse forex effects will lower adjusted ebitda by 0-00%. Merck is rated "Unattractive" in our US Large-Cap Global Top Stock Ideas. 